Bronchodilator Responsiveness in Tobacco-Exposed Persons with or without COPD

By sjmartinez • November 18, 2022

Fortis S, Quibrera PM, Comellas AP, Bhatt SP, Tashkin DP, Hoffman EA, Criner GJ, Han MK, Barr RG, Arjomandi M, Dransfield MB, Peters SP, Dolezal BA, Kim V, Putcha N, Rennard SI, Paine R 3rd, Kanner RE, Curtis JL, Bowler RP, Martinez FJ, Hansel NN, Krishnan JA, Woodruff PG, Barjaktarevic IZ, Couper D, Anderson WH, Cooper CB. Bronchodilator Responsiveness in Tobacco-Exposed Persons with or without COPD. Chest. 2022 Nov 14:S0012-3692(22)04077-6. doi: 10.1016/j.chest.2022.11.009. Epub ahead of print. PMID: 36395858.

Tags: bronchodilator, bronchodilator response, bronchodilator responsiveness, bronchodilator reversibility, COPD, Publications, Pulmonary, Critical Care & Sleep Medicine

Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review

Leiva O, Liu O, Kanelidis A, Swat S, Gozdecki L, Belkin M, Grinstein J, Kalantari S, Kim G, DeCara J, Chung B, Patel A, Odenike[...]

Self-Reported Resilience During the COVID-19 Pandemic

Ogungbe O, Wang T, Balte PP, Slone SE, Meyer D, Allen NB, Buhr RG, Hirsch JA, Hinckley Stukovsky K, Kucharska-Newton A, Gabriel KP, Regan EA,[...]

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma

Armand P, Zinzani PL, Timmerman JM, Johnson NA, Lavie D, Thiagarajan K, Topp B, Pillai PM, Herrera AF. Estimating efficacy of favezelimab plus pembrolizumab relative[...]